The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Adeno-Associated Virus (AAV) Vector-Based Gene Therapy-Global Market Insights and Sales Trends 2024
Synopsis
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size is expected to reach US$ 1106.4 million by 2029, growing at a CAGR of 5.4% from 2023 to 2029. The market is mainly driven by the significant applications of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in various end use industries. The expanding demands from the Hemophilia, Ophthalmology, Lysosomal Storage Disorders and Neurological Disorders, are propelling Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. Single-stranded AAV (ssAAV), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Self-complementary AAV (scAAV) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy covered in this report include BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics and Neurocrine Biosciences, etc.
The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, Segment by Type:
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, by Application
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
AAV is transformed from a naturally occurring virus into a delivery mechanism for gene therapy. The viral DNA is replaced with new DNA, and it becomes a precisely coded vector and is no longer considered a virus, as most of the viral components have been replaced. The AAV Vector-Based Gene Therapy market size is anticipated to shoot up exponentially attributing to an increase in the approval of a growing number of gene therapies and readily adoption on approval, ability to treat a broad array of conditions, increasing prevalence of diseases, convenient one-time dosing approach and curative treatment options.
The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market size is expected to reach US$ 1106.4 million by 2029, growing at a CAGR of 5.4% from 2023 to 2029. The market is mainly driven by the significant applications of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy in various end use industries. The expanding demands from the Hemophilia, Ophthalmology, Lysosomal Storage Disorders and Neurological Disorders, are propelling Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market. Single-stranded AAV (ssAAV), one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Self-complementary AAV (scAAV) segment is estimated at % CAGR for the next seven-year period.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Adeno-Associated Virus (AAV) Vector-Based Gene Therapy, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy covered in this report include BioMarin Pharmaceutical, Sangamo Therapeutics, Amicus Therapeutics, Roche, Pfizer, NightstaRx, MeiraGTx, Sarepta Therapeutics and Neurocrine Biosciences, etc.
The global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
BioMarin Pharmaceutical
Sangamo Therapeutics
Amicus Therapeutics
Roche
Pfizer
NightstaRx
MeiraGTx
Sarepta Therapeutics
Neurocrine Biosciences
Voyager Therapeutics
Asklepios Biopharmaceutical
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, Segment by Type:
Single-stranded AAV (ssAAV)
Self-complementary AAV (scAAV)
Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy market, by Application
Hemophilia
Ophthalmology
Lysosomal Storage Disorders
Neurological Disorders
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Adeno-Associated Virus (AAV) Vector-Based Gene Therapy
1.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Overview
1.1.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Scope
1.1.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Status and Outlook
1.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2029)
1.4 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Region (2018-2023)
1.5 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
1.6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
1.6.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
1.6.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
1.6.4 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
1.6.5 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size (2018-2029)
2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market by Type
2.1 Introduction
2.1.1 Single-stranded AAV (ssAAV)
2.1.2 Self-complementary AAV (scAAV)
2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Type (2018-2023)
2.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Breakdown by Type (2018-2029)
3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Overview by Application
3.1 Introduction
3.1.1 Hemophilia
3.1.2 Ophthalmology
3.1.3 Lysosomal Storage Disorders
3.1.4 Neurological Disorders
3.1.5 Others
3.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Historic Market Size by Application (2018-2023)
3.2.2 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue Breakdown by Application (2018-2029)
4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Competition Analysis by Players
4.1 Global Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Adeno-Associated Virus (AAV) Vector-Based Gene Therapy as of 2022)
4.3 Date of Key Players Enter into Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market
4.4 Global Top Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Headquarters and Area Served
4.5 Key Players Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Product Solution and Service
4.6 Competitive Status
4.6.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 BioMarin Pharmaceutical
5.1.1 BioMarin Pharmaceutical Profile
5.1.2 BioMarin Pharmaceutical Main Business
5.1.3 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.1.4 BioMarin Pharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.1.5 BioMarin Pharmaceutical Recent Developments
5.2 Sangamo Therapeutics
5.2.1 Sangamo Therapeutics Profile
5.2.2 Sangamo Therapeutics Main Business
5.2.3 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.2.4 Sangamo Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.2.5 Sangamo Therapeutics Recent Developments
5.3 Amicus Therapeutics
5.3.1 Amicus Therapeutics Profile
5.3.2 Amicus Therapeutics Main Business
5.3.3 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.3.4 Amicus Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.3.5 Roche Recent Developments
5.4 Roche
5.4.1 Roche Profile
5.4.2 Roche Main Business
5.4.3 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.4.4 Roche Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.4.5 Roche Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.5.4 Pfizer Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.5.5 Pfizer Recent Developments
5.6 NightstaRx
5.6.1 NightstaRx Profile
5.6.2 NightstaRx Main Business
5.6.3 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.6.4 NightstaRx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.6.5 NightstaRx Recent Developments
5.7 MeiraGTx
5.7.1 MeiraGTx Profile
5.7.2 MeiraGTx Main Business
5.7.3 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.7.4 MeiraGTx Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.7.5 MeiraGTx Recent Developments
5.8 Sarepta Therapeutics
5.8.1 Sarepta Therapeutics Profile
5.8.2 Sarepta Therapeutics Main Business
5.8.3 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.8.4 Sarepta Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.8.5 Sarepta Therapeutics Recent Developments
5.9 Neurocrine Biosciences
5.9.1 Neurocrine Biosciences Profile
5.9.2 Neurocrine Biosciences Main Business
5.9.3 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.9.4 Neurocrine Biosciences Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.9.5 Neurocrine Biosciences Recent Developments
5.10 Voyager Therapeutics
5.10.1 Voyager Therapeutics Profile
5.10.2 Voyager Therapeutics Main Business
5.10.3 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.10.4 Voyager Therapeutics Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.10.5 Voyager Therapeutics Recent Developments
5.11 Asklepios Biopharmaceutical
5.11.1 Asklepios Biopharmaceutical Profile
5.11.2 Asklepios Biopharmaceutical Main Business
5.11.3 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Products, Services and Solutions
5.11.4 Asklepios Biopharmaceutical Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Revenue (US$ Million) & (2018-2023)
5.11.5 Asklepios Biopharmaceutical Recent Developments
6 North America
6.1 North America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2029)
6.2 United States
6.3 Canada
7 Europe
7.1 Europe Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Dynamics
11.1 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Industry Trends
11.2 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Drivers
11.3 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Challenges
11.4 Adeno-Associated Virus (AAV) Vector-Based Gene Therapy Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
